What question did this study set out to answer?

This research aims to evaluate whether the CRP to albumin ratio can stratify treatment response and survival in non-Hodgkin's lymphoma patients undergoing CAR T therapy.

December 8, 2025BloodOpen Access

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

View Full Paper

Ask AI

Bookmark

Authors

RLRichard J. LinMemorial Sloan Kettering Cancer Center APAllison ParascondolaMemorial Sloan Kettering Cancer Center MGMika GevaMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Retrospective study shows CRP to albumin ratio predicts treatment response and survival in non-Hodgkin's lymphoma, indicating its role as a prognostic marker in CAR T therapy.

Key Points

This research aims to evaluate whether the CRP to albumin ratio can stratify treatment response and survival in non-Hodgkin's lymphoma patients undergoing CAR T therapy.
Performed a retrospective analysis of patients with R/R non-Hodgkin's lymphoma treated with CAR T therapy.
Utilized Cox proportional hazards models for multivariable analysis of treatment outcomes.
Analyzed associations between pre-infusion CAR values and clinical characteristics using statistical tests.
Higher pre-lymphodepletion CAR is independently associated with increased overall survival and progression-free survival after adjusting for other risk factors.
Patients with higher LDH levels had poorer outcomes, indicating its prognostic value.
CRP to albumin ratio may help predict relapse and survival outcomes in non-Hodgkin's lymphoma patients receiving CAR T therapy.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d691 https://doi.org/10.1182/blood-2025-7090

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study shows CRP to albumin ratio predicts treatment response and survival in non-Hodgkin's lymphoma, indicating its role as a prognostic marker in CAR T therapy.

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider